Trial Profile
A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Apr 2021
Price :
$35
*
At a glance
- Drugs Olitigaltin (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Proof of concept
- Sponsors Galecto Biotech
- 23 Mar 2021 According to a Galecto Inc media release, the company will host an expert perspectives panel on the evolving treatment landscape for idiopathic pulmonary fibrosis (IPF) and the potential for GB0139 on March 30, 2021. The webinar will feature a presentation by Key Opinion Leader (KOL) Toby Maher, who will discuss the clinical meaning of the exciting biomarker data on GB0139 recently published in the European Respiratory Journal.
- 16 Mar 2021 Time frame for primary endpoint changed from 2 weeks to 30 days.
- 30 Nov 2020 Results presented in a Galecto Biotech Media Release.